Company news

KalVista Pharmaceuticals, Inc. news in 2025

KalVista Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

December 21, 2025

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

November 9, 2025

KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

November 5, 2025

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

November 4, 2025

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

November 2, 2025

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

October 29, 2025

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

October 5, 2025

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

October 5, 2025

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

October 1, 2025

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

September 25, 2025

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

September 23, 2025

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

September 23, 2025

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

September 18, 2025

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

September 10, 2025

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

September 3, 2025

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

August 26, 2025

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

August 10, 2025

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

July 24, 2025

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

July 14, 2025

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

July 9, 2025

DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals' Ekterly® (sebetralstat)

July 8, 2025

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)

July 7, 2025

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

July 6, 2025

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

June 25, 2025

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

June 15, 2025

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

June 12, 2025

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

June 4, 2025

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

June 1, 2025

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 28, 2025

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

May 21, 2025

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

April 29, 2025

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

April 7, 2025

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

March 30, 2025

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

March 24, 2025

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

March 11, 2025

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

March 9, 2025

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

March 2, 2025

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

February 20, 2025

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

February 9, 2025

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

January 20, 2025

Calls in 2025

Decks in 2025